Vistagen Faces Securities Lawsuit Over Fasedienol Drug Claims
Vistagen Therapeutics faces securities lawsuit over alleged fasedienol misstatements. Investors who purchased VTGN stock April 2024-December 2025 may be eligible for compensation; lead plaintiff deadline is March 16, 2026.
VTGNPhase 3 clinical trialsecurities class action